ALZEVIT study is sponsored by Firalis, who is a French company that has developed APOE-Easy kit dedicated to analyze the APOE genotyping in a very easy way. And they have also developed a lot of different blood-based biomarkers to better understand disease. So ALZEVIT, it’s really aimed to focus on the APOE homozygote participants because we are thinking it’s a very, very relevant and important target...
ALZEVIT study is sponsored by Firalis, who is a French company that has developed APOE-Easy kit dedicated to analyze the APOE genotyping in a very easy way. And they have also developed a lot of different blood-based biomarkers to better understand disease. So ALZEVIT, it’s really aimed to focus on the APOE homozygote participants because we are thinking it’s a very, very relevant and important target. And the patient needs to have specific study that analyzes their cognitive trajectories and functional trajectory, and also to be able to make a reservoir of such individuals to propose them clinical trials or new treatment. So as you know, there is APOE. It’s at the beginning a risk factor for Alzheimer’s disease, but now recent publications show that it’s potentially a genetic form of AD. And due to different factors and arguments, we think that there is a great opportunity to target APOE homozygote population. And the ALZEVIT study, it’s a fully decentralized platform aiming to recruit in a French population 50,000 individuals and in a fully decentralized manner with the APOE-Easy kit. Then we select, based on different range of age, some individuals that will be confirmed in a way or analyzed more in depth in the phenotyping part two. That it’s also a hybrid aspect with tele-research consultation and confirmation in memory center. So the aim is really to have an online platform able to analyze distribution at a population level of APOE, homozygote, heterozygote, and other status. And also to be able to analyze their cognitive trajectories, their biomarker profile, and also the other risk that could lead to a faster decline or to some preventive intervention. And then to propose them personalized approach to be able to really slow down the progression and act on these very specific cases. As you know, they are unfortunately ruled out for many treatments, actually, in particular, the anti-amyloid treatment due to higher risk. So this factor, and in particular, this population, it’s of such importance. They carry out the burden of Alzheimer’s. They have familial history for most of the time and they know what lies ahead and they really want to be part of a therapeutic journey and act. They have not got the luxury of waiting for the perfect treatment. So that’s why we want to propose personalized and preventive strategy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
